{"title":"维生素D缺乏和代谢综合征:与他汀类药物不耐受和脂肪因子失调有关吗?","authors":"N. Katsiki, A. Sahebkar, M. Banach","doi":"10.1080/17584299.2016.1243651","DOIUrl":null,"url":null,"abstract":"We read with interest the Miñambres et al. review on hypovitaminosis D and the metabolic syndrome (MetS).[1] The authors describe evidence linking vitamin D (vit D) deficiency with MetS or its components, whereas inconsistent results have been reported with regard to vit D supplementation effects on metabolic parameters. The authors suggested that further research is needed to establish whether improving MetS components can increase vit D levels and vice versa. Vit D deficiency has been associated with statin-induced adverse effects.[reviewed in 2,3] In this context, a recent meta-analysis found that low vit D concentrations were related to myalgia in statin-treated patients.[4] Vit D supplementation has also been proposed as an option to manage statin intolerance in patients with vit D deficiency.[5] As MetS patients are at a high cardiovascular (CV) risk, they are often treated with statins.[6] Based on the link between MetS and vit D hypovitaminosis, it follows that measuring vit D levels may be clinically useful in MetS patients to either prevent or treat statin intolerance. In this context, it is also worth noting that statins can interfere with vit D metabolism through CYP3A4,[7] and also increase the availability of cholesterol biosynthesis precursors such as 7-dehydrocholesterol that mediate vitamin D production.[8] These interactions could confound the association between vit D status and MetS and should be considered before interpreting any observational data. On another issue, MetS has been associated with decreased adiponectin and increased leptin levels.[9] These adipokine abnormalities may further increase CV risk in MetS patients.[9] Vit D metabolism has been reported to influence the expression of leptin and adiponectin in adipose tissue.[10] In this context, there are data linking vit D positively with adiponectin and negatively with leptin levels.[11–13] However, a recent meta-analysis did not find any effect of vit D intake on leptin and adiponectin concentrations.[14] Further research is needed to elucidate such associations.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"15 1","pages":"23 - 24"},"PeriodicalIF":0.0000,"publicationDate":"2016-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Vitamin D deficiency and metabolic syndrome: any link with statin intolerance and adipokines dysregulation?\",\"authors\":\"N. Katsiki, A. Sahebkar, M. Banach\",\"doi\":\"10.1080/17584299.2016.1243651\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We read with interest the Miñambres et al. review on hypovitaminosis D and the metabolic syndrome (MetS).[1] The authors describe evidence linking vitamin D (vit D) deficiency with MetS or its components, whereas inconsistent results have been reported with regard to vit D supplementation effects on metabolic parameters. The authors suggested that further research is needed to establish whether improving MetS components can increase vit D levels and vice versa. Vit D deficiency has been associated with statin-induced adverse effects.[reviewed in 2,3] In this context, a recent meta-analysis found that low vit D concentrations were related to myalgia in statin-treated patients.[4] Vit D supplementation has also been proposed as an option to manage statin intolerance in patients with vit D deficiency.[5] As MetS patients are at a high cardiovascular (CV) risk, they are often treated with statins.[6] Based on the link between MetS and vit D hypovitaminosis, it follows that measuring vit D levels may be clinically useful in MetS patients to either prevent or treat statin intolerance. In this context, it is also worth noting that statins can interfere with vit D metabolism through CYP3A4,[7] and also increase the availability of cholesterol biosynthesis precursors such as 7-dehydrocholesterol that mediate vitamin D production.[8] These interactions could confound the association between vit D status and MetS and should be considered before interpreting any observational data. On another issue, MetS has been associated with decreased adiponectin and increased leptin levels.[9] These adipokine abnormalities may further increase CV risk in MetS patients.[9] Vit D metabolism has been reported to influence the expression of leptin and adiponectin in adipose tissue.[10] In this context, there are data linking vit D positively with adiponectin and negatively with leptin levels.[11–13] However, a recent meta-analysis did not find any effect of vit D intake on leptin and adiponectin concentrations.[14] Further research is needed to elucidate such associations.\",\"PeriodicalId\":55252,\"journal\":{\"name\":\"Clinical Lipidology\",\"volume\":\"15 1\",\"pages\":\"23 - 24\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-10-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lipidology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17584299.2016.1243651\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lipidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17584299.2016.1243651","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}
Vitamin D deficiency and metabolic syndrome: any link with statin intolerance and adipokines dysregulation?
We read with interest the Miñambres et al. review on hypovitaminosis D and the metabolic syndrome (MetS).[1] The authors describe evidence linking vitamin D (vit D) deficiency with MetS or its components, whereas inconsistent results have been reported with regard to vit D supplementation effects on metabolic parameters. The authors suggested that further research is needed to establish whether improving MetS components can increase vit D levels and vice versa. Vit D deficiency has been associated with statin-induced adverse effects.[reviewed in 2,3] In this context, a recent meta-analysis found that low vit D concentrations were related to myalgia in statin-treated patients.[4] Vit D supplementation has also been proposed as an option to manage statin intolerance in patients with vit D deficiency.[5] As MetS patients are at a high cardiovascular (CV) risk, they are often treated with statins.[6] Based on the link between MetS and vit D hypovitaminosis, it follows that measuring vit D levels may be clinically useful in MetS patients to either prevent or treat statin intolerance. In this context, it is also worth noting that statins can interfere with vit D metabolism through CYP3A4,[7] and also increase the availability of cholesterol biosynthesis precursors such as 7-dehydrocholesterol that mediate vitamin D production.[8] These interactions could confound the association between vit D status and MetS and should be considered before interpreting any observational data. On another issue, MetS has been associated with decreased adiponectin and increased leptin levels.[9] These adipokine abnormalities may further increase CV risk in MetS patients.[9] Vit D metabolism has been reported to influence the expression of leptin and adiponectin in adipose tissue.[10] In this context, there are data linking vit D positively with adiponectin and negatively with leptin levels.[11–13] However, a recent meta-analysis did not find any effect of vit D intake on leptin and adiponectin concentrations.[14] Further research is needed to elucidate such associations.
期刊介绍:
The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.